MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.57
-0.49
-4.87%
Closed 16:03 06/28 EDT
OPEN
9.91
PREV CLOSE
10.06
HIGH
10.09
LOW
9.05
VOLUME
123.46K
TURNOVER
--
52 WEEK HIGH
45.56
52 WEEK LOW
6.05
MARKET CAP
446.62M
P/E (TTM)
-4.1767
1D
5D
1M
3M
1Y
5Y
ELMS, EMWP and EOSE among mid-day movers
Gainers: Electric Last Mile Solutions (ELMS) +195%. Advent Technologies Holdings (ADN) +185%. Sidus Space (SIDU) +60%. Pennsylvania Real Estate Investment (PEI) +39%. Vivakor (VIVK) +32%. Akero (AKRO) +24%. Revlon (REV)
Seekingalpha · 06/16 16:54
Upcoming 220K-square-foot South End lab project almost fully leased
The BPDA cleared the way last summer for a roughly 220,000-square-foot lab and research-and-development site in a neighborhood that is seeing an influx of life sciences space.
American City Business Journals · 06/14 09:16
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating
MT Newswires · 05/12 05:54
Monte Rosa Therapeutics GAAP EPS of -$0.51 beats by $0.03
Monte Rosa Therapeutics press release (NASDAQ:GLUE): GAAP EPS of -$0.51 beats by $0.03. Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2022, were $322.5 million, compared to cash, cash
Seekingalpha · 05/11 12:00
BRIEF-Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results And Business Updates
reuters.com · 05/11 11:34
Monte Rosa Therapeutics Q1 Net Loss Narrows
MT Newswires · 05/11 08:03
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Benzinga · 04/28 14:09
--Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target
MT Newswires · 04/28 11:14
More
No Data
Learn about the latest financial forecast of GLUE. Analyze the recent business situations of Monte Rosa Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
50.00%Buy
37.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GLUE stock price target is 24.43 with a high estimate of 38.00 and a low estimate of 15.00.
High38.00
Average24.43
Low15.00
Current 10.01
EPS
Actual
Estimate
-2.90-2.18-1.45-0.73
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 52
Institutional Holdings: 38.54M
% Owned: 82.59%
Shares Outstanding: 46.67M
TypeInstitutionsShares
Increased
25
4.65M
New
10
341.61K
Decreased
7
17.29K
Sold Out
11
1.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.86%
Key Executives
Non-Executive Chairman/Director
Alexander Mayweg
President/Chief Executive Officer/Director
Markus Warmuth
Chief Financial Officer
Ajim Tamboli
Chief Technology Officer
Sharon Townson
Chief Scientific Officer
Owen Wallace
General Counsel
Philip Nickson
Other
John Castle
Other
Filip Janku
Other
Jullian Jones
Independent Director
Ali Behbahani
Independent Director
Kimberly Blackwell
Independent Director
Chandra Leo
Independent Director
Andrew Schiff
Independent Director
Christine Siu
No Data
No Data
About GLUE
Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. It utilizes its Quantitative and Engineered Elimination of Neosubstrates (QuEEN), platform to design novel MGDs focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways across clinical indications in oncology and non-oncology, including immunology, inflammation, neurological and genetic diseases.

Webull offers kinds of Monte Rosa Therapeutics Inc stock information, including NASDAQ:GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.